Latest News | Bharat Biotech, Ocugen Committed to Bring COVID-19 Vaccine Covaxin in US, Canada

New Delhi, Mar 7 (PTI) Bharat Biotech on Monday said it, along with its partner Ocugen, is fully committed to bringing COVID-19 vaccine Covaxin in the US and Canada for all age groups.

In a statement issued on Twitter, the Hyderabad-based vaccine major said Ocugen's Phase 2/3 Investigational Drug Application for Covaxin has been recently cleared by the US Food and Drug Administration(USFDA) for conducting clinical trials in adults.

Also Read | Inbase Launches Urban Lyf M Affordable Smartwatch in India.

"Ocugen intends to continue working with FDA to evaluate regulatory pathways for the pediatric use of Covaxin," it added.

On March 4, Ocugen Inc had announced that the USFDA has declined to issue a EUA for Covaxin for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals -- 2 to 18 years of age.

Also Read | Google Pixel 6a Specifications Leaked via Geekbench: Report.

Last month, Bharat Biotech had announced that Covaxin would be assessed in the United States as a COVID-19 vaccine candidate.

Ocugen Inc, the company's US and Canadian partner for Covaxin, had stated earlier that the US health regulator has withdrawn its clinical hold to study the COVID-19 vaccine candidate BBV152, known as Covaxin outside the US.

Covaxin (BBVI52), developed by Bharat Biotech in conjunction with the Indian Council of Medical Research (ICMR), is a vaccine candidate currently under evaluation in the US.

In the US and Canada, Ocugen Inc is co-developing the Covaxin vaccine candidate for COVID-19.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)